Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies.

This document provides a summary of a study on the use of tofacitinib in patients with psoriasis and a history of psoriatic arthritis (PsA). The study found that tofacitinib, at both 5mg and 10mg doses, resulted in significant improvements in skin disease, itch, joint pain, morning stiffness, and depressive symptoms compared to a placebo. The safety profile of tofacitinib was consistent with previous reports. The study suggests that these findings can inform clinical practice and the scientific community. The limitations of the study include the reliance on patient reports for PsA history. The study was sponsored by Pfizer, and the authors disclosed various conflicts of interest. [Extracted from the article]